Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

GLAXOSMITHKLINE PLC (GSK)

156
Delayed Quote. Delayed London Stock Exchange - 10/31 12:35:05 pm
1417.5 GBp   +1.39%
14h ago Regus forecasts capex below estimates, eases fears over debt
3d ago Sanofi shares sink as diabetes sales slow, CEO pressured
3d ago GLAXOSMITHKLINE : *kepler cheuvreux raises glaxosmithkline price target to ..
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M GBP Estimates in M GBP
Fiscal Period December 201120122013201420152016
Sales27 38726 43126 50523 30624 74925 533
Operating income (EBITDA)10 2319 4158 8837 8798 0558 482
Operating profit (EBIT)8 5548 3308 0156 5096 7637 106
Pre-Tax Profit (EBT)7 6986 6926 6474 8225 4145 959
Net income5 2614 5655 6283 5703 5513 969
EPS (PNC)10391,511173,188,182,8
Dividend per Share (PNC)70,074,078,080,281,182,9
Yield5,01%5,29%5,58%5,74%5,80%5,93%
Announcement Date02/07/2012
12:00pm
02/06/2013
12:01pm
02/05/2014
12:00pm
---
Finances - Leverage
Actuals in M GBP Estimates in M GBP
Fiscal Period December 201120122013201420152016
Debt9 00314 03712 64512 80611 10811 023
Finance------
Operating income (EBITDA)10 2319 4158 8837 8798 0558 482
Leverage
(Debt/EBITDA)
0,88x1,49x1,42x1,63x1,38x1,30x
Capital Expenditure9231 0511 1881 3941 4411 458
Book Value Per Share (BVPS)162 PNC120 PNC146 PNC137 PNC141 PNC145 PNC
Cash Flow per Share124 PNC87,7 PNC149 PNC102 PNC117 PNC138 PNC
Announcement Date02/07/2012
12:00pm
02/06/2013
12:01pm
02/05/2014
12:00pm
---
Balance Sheet Analysis
Assessed data source :
© 2014 Thomson Reuters
Advertisement
Financial Ratios

Size 2014e 2015e
Capitalization 67 800 M GBP -
Entreprise Value (EV) 80 606 M GBP 78 908 M GBP
Valuation 2014e 2015e
PER (Price / EPS) 19,1x 15,9x
Capitalization / Revenue 2,91x 2,74x
EV / Revenue 3,46x 3,19x
EV / EBITDA 10,2x 9,80x
Yield (DPS / Price) 5,74% 5,80%
Profitability 2014e 2015e
Operating Margin (EBIT / Sales) 27,9% 27,3%
operating Leverage (Delta EBIT / Delta Sales) -1,56x 0,63x
Net Margin (Net Profit / Revenue) 15,3% 14,3%
ROA (Net Profit / Asset) 7,60% 7,85%
ROE (Net Profit / Equities) 61,2% 69,2%
Rate of Dividend 110% 92,1%
Balance Sheet Analysis 2014e 2015e
CAPEX / Sales   5,98% 5,82%
Cash Flow / Sales (Taux d'autofinancement) 21,3% 23,0%
Capital Intensity (Assets / Sales) 2,02x 1,83x
Financial Leverage (Net Debt / EBITDA) 1,63x 1,38x
Price Earning Ratio
EPS & Dividend
Dynamic quotes  
ON
| OFF